Aclarion, Inc. (ACON): Cash & Equivalents
$12.02M
As of 2025-12-31
$16.29M
As of 2026-06-30
+101.3%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.02M | n/m | 2026-03-18, Balance as of period end |
| 2024-12-31 | $453.7K | -55.6% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $1.02M | -30.7% | 2025-04-09, Balance as of period end |
| 2022-12-31 | $1.47M | +240.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $432.5K | n/a | 2023-06-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aclarion, Inc. (ACON) | 2025-12-31 | $12.02M | n/m |
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $3.94M | -2.4% |
| YD Bio Ltd (YDES) | 2025-12-31 | $6.01M | +91.8% |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $2.49M | -13.9% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $3.46M | -68.6% |
| CapForce Inc. (CFOR) | 2025-12-31 | $531.3K | -59.5% |
| Exagen Inc. (XGN) | 2025-12-31 | $32.22M | +46.2% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $124.25M | +35.9% |
| Biodesix Inc (BDSX) | 2025-12-31 | $18.99M | -27.7% |
Compare ACON, SERA, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗